Rosuvastatin Gel With 1:1 Mixture of Platelet-rich Fibrin and Bone Graft in Mandibular Degree II Furcation Defects
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Rosuvastatin (RSV) is a new synthetic, second-generation, sulfur-containing, hydrophilic
statin, that stimulate bone formation in critical-size cortical bone defects adjacent to
titanium implants, when administered locally in bone. Platelet-rich fibrin (PRF) is a
platelet concentrate with sustained release of various growth factors, having regenerative
potential to treat periodontal defects. Porous hydroxyapatite (HA) bone grafting material has
clinically satisfactory response, when used to fill periodontal intrabony defects. This
double-masked randomized study is designed to evaluate the potency of combination of RSV
1.2mg in situ gel with 1:1 mixture of autologous PRF and HA bone graft in the surgical
treatment of mandibular degree II furcation defects when compared with autologous PRF and HA
bone graft placed after open flap debridement (OFD).
Phase:
Phase 4
Details
Lead Sponsor:
Government Dental College and Research Institute, Bangalore